Cargando…

Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review

Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally. Early studies on bnAbs showed safety in humans, but short elimination half-lives and low potency and breadth. Since 2010,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahomed, Sharana, Garrett, Nigel, Baxter, Cheryl, Abdool Karim, Quarraisha, Abdool Karim, Salim S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508778/ https://www.ncbi.nlm.nih.gov/pubmed/32604408 http://dx.doi.org/10.1093/infdis/jiaa377

Ejemplares similares

Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
por: Mahomed, Sharana, et al.
Publicado: (2022)

Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives
por: Baxter, Cheryl, et al.
Publicado: (2021)

Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial
por: Mahomed, Sharana, et al.
Publicado: (2019)

COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa
por: Abdool Karim, Quarraisha, et al.
Publicado: (2022)

Mechanisms of sexually transmitted infection‐induced inflammation in women: implications for HIV risk
por: Mwatelah, Ruth, et al.
Publicado: (2019)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies
por: Sheward, Daniel J., et al.
Publicado: (2022)

Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies
por: Mabvakure, Batsirai M., et al.
Publicado: (2019)

Microbicides & their implications in HIV prevention
por: Karim, Salim S. Abdool, et al.
Publicado: (2010)

HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth
por: Sheward, Daniel J., et al.
Publicado: (2018)

Current status of the HIV epidemic & challenges in prevention
por: Karim, Quarraisha Abdool
Publicado: (2017)

Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
por: Mahomed, Sharana, et al.
Publicado: (2020)

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022)

Inclusion of adolescent girls in HIV prevention research – an imperative for an AIDS-free generation
por: Karim, Quarraisha Abdool, et al.
Publicado: (2014)

HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies
por: Richardson, Simone I., et al.
Publicado: (2018)

Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope
por: Anthony, Colin, et al.
Publicado: (2017)

IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
por: Richardson, Simone I., et al.
Publicado: (2019)

Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women
por: Mngomezulu, Khanyisile, et al.
Publicado: (2021)

Higher mucosal antibody concentrations in women with genital tract inflammation
por: Sobia, Parveen, et al.
Publicado: (2021)

Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women
por: Fisher, Kimone Leigh, et al.
Publicado: (2020)

COVID-19 in Africa: Catalyzing change for sustainable development
por: Abdool Karim, Salim S., et al.
Publicado: (2021)

Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial
por: Succop, Stacey M., et al.
Publicado: (2014)

Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case–Control Study
por: MacQueen, Kathleen M., et al.
Publicado: (2014)

ARV-based HIV prevention for women – where we are in 2014
por: Mastro, Timothy D, et al.
Publicado: (2014)

Low adverse event rates following voluntary medical male circumcision in a high HIV disease burden public sector prevention programme in South Africa
por: Phili, Rogerio, et al.
Publicado: (2014)

Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection
por: Naranbhai, Vivek, et al.
Publicado: (2013)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression
por: Ngcobo, Samukelisiwe, et al.
Publicado: (2022)

CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women
por: Gengiah, Tanuja Narayansamy, et al.
Publicado: (2022)

Identification of adolescent girls and young women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South Africa
por: Ayton, Sarah Gabrielle, et al.
Publicado: (2020)

High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa
por: Msomi, Nokukhanya, et al.
Publicado: (2020)

HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition
por: Liebenberg, Lenine J. P., et al.
Publicado: (2019)

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
por: Karim, Quarraisha Abdool, et al.
Publicado: (2011)

Enhancing oral PrEP uptake among adolescent girls and young women in Africa
por: Heck, Craig J., et al.
Publicado: (2022)

A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage
por: Kitchin, D, et al.
Publicado: (2019)

Enrolling Adolescents in Research on HIV and Other Sensitive Issues: Lessons from South Africa
por: Singh, Jerome Amir, et al.
Publicado: (2006)

HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services
por: Kharsany, Ayesha BM, et al.
Publicado: (2012)

Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide
por: Ngandu, Nobubelo K., et al.
Publicado: (2017)

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial
por: Mansoor, Leila E, et al.
Publicado: (2014)

Honing in on enteric fever
por: McKinnon, Lyle R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kmgof4ifb20trte7kh7sehdguj